Mild cognitive impairment and on to dementia
Down the slippery slope but faster
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In this issue of Neurology®, a study from the Chicago Health and Aging Project shows that persons with dementia of the Alzheimer type (DAT) decline more rapidly than persons with mild cognitive impairment (MCI), and that patients with MCI decline more rapidly than cognitively normal persons.1 The findings have important implications for understanding the relationships between the clinical manifestations and the pathology of Alzheimer disease (AD).
In longitudinal studies, there is an acceleration of decline in cognition preceding the diagnosis of dementia.2,3 The observations of Wilson et al.1 on the differences between normal cognition and MCI are consistent with these prior observations. The finding of acceleration of decline between MCI and DAT has not been previously established in persons with incident cognitive impairment. Clinical trial experience in MCI and DAT certainly shows differences in rates of progression between the 2 groups. Patient groups with prevalent MCI or DAT are more likely to include some persons with static conditions. In contrast, incident cases are those persons who, by definition, are exhibiting recently recognized decline. By studying incident cases of MCI, Wilson et al. have a reasonable assurance that they have identified persons with MCI who have a progressive condition. In addition, the Chicago Health …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Alert Me
Recommended articles
-
Articles
Normative estimates of cross-sectional and longitudinal brain volume decline in aging and ADA. F. Fotenos, A. Z. Snyder, L. E. Girton et al.Neurology, March 21, 2005 -
Articles
CSF biomarkers of Alzheimer disease in HIV-associated neurologic diseaseD. B. Clifford, A. M. Fagan, D. M. Holtzman et al.Neurology, November 11, 2009 -
Articles
[11C]PIB in a nondemented populationPotential antecedent marker of Alzheimer diseaseM. A. Mintun, G. N. LaRossa, Y. I. Sheline et al.Neurology, August 07, 2006 -
Article
CSF excitatory amino acids and severity of illness in Alzheimer's diseaseJ. G. Csernansky, M. E. Bardgett, Y. I. Sheline et al.Neurology, June 01, 1996